Eckert & Ziegler will provide its Lutetium-177 chloride to support AtomVie's CDMO activities for radiopharmaceutical ...

Eckert & Ziegler SE (ISIN DE0005659700, SDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply ...

20.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution ...

Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have announced a significant global supply agreement aimed at supporting AtomVie’s ...

Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, ...

Scientists from Tomsk Polytechnic University, in collaboration with their colleagues, supported by the federal Priority-2030 ...

In combination with the promising Phase 1 data for Lutetium (177 Lu) rhPSMA-10.1 Injection, these design factors should further support the aim of maximizing treatment response and therefore may ...

Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...

1,2 The Phase 1 data shows that Lutetium (177 Lu) rhPSMA-10.1 Injection has high ratios for absorbed radiation dose to tumours vs. dose to healthy tissues, with a measured mean tumour to salivary ...

Nuclear power has long been a reliable energy source, supplying nearly 20% of electricity in the United States. While it does ...

As federal and state governments look for ways to save money, there is one project Missouri sees fit for extra investments: ...